208 related articles for article (PubMed ID: 19025451)
1. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer.
Saad M; Garbuzenko OB; Minko T
Nanomedicine (Lond); 2008 Dec; 3(6):761-76. PubMed ID: 19025451
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of cell proliferation through an ATP-responsive co-delivery system of doxorubicin and Bcl-2 siRNA.
Zhang J; Wang Y; Chen J; Liang X; Han H; Yang Y; Li Q; Wang Y
Int J Nanomedicine; 2017; 12():4721-4732. PubMed ID: 28740380
[TBL] [Abstract][Full Text] [Related]
3. Combinatorial therapeutic approaches with RNAi and anticancer drugs using nanodrug delivery systems.
Babu A; Munshi A; Ramesh R
Drug Dev Ind Pharm; 2017 Sep; 43(9):1391-1401. PubMed ID: 28523942
[TBL] [Abstract][Full Text] [Related]
4. Liposomal nanocarriers containing siRNA as small molecule-based drugs to overcome cancer drug resistance.
Safaei M; Khalighi F; Behabadi FA; Abpeikar Z; Goodarzi A; Kouhpayeh SA; Najafipour S; Ramezani V
Nanomedicine (Lond); 2023 Oct; 18(24):1745-1768. PubMed ID: 37965906
[TBL] [Abstract][Full Text] [Related]
5. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo.
Meng H; Mai WX; Zhang H; Xue M; Xia T; Lin S; Wang X; Zhao Y; Ji Z; Zink JI; Nel AE
ACS Nano; 2013 Feb; 7(2):994-1005. PubMed ID: 23289892
[TBL] [Abstract][Full Text] [Related]
6. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells.
Chen AM; Zhang M; Wei D; Stueber D; Taratula O; Minko T; He H
Small; 2009 Dec; 5(23):2673-7. PubMed ID: 19780069
[No Abstract] [Full Text] [Related]
7. Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA.
Taratula O; Garbuzenko OB; Chen AM; Minko T
J Drug Target; 2011 Dec; 19(10):900-14. PubMed ID: 21981718
[TBL] [Abstract][Full Text] [Related]
8. Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.
Gandhi NS; Tekade RK; Chougule MB
J Control Release; 2014 Nov; 194():238-56. PubMed ID: 25204288
[TBL] [Abstract][Full Text] [Related]
9. Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin.
Xiong XB; Lavasanifar A
ACS Nano; 2011 Jun; 5(6):5202-13. PubMed ID: 21627074
[TBL] [Abstract][Full Text] [Related]
10. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer.
Chen Y; Bathula SR; Li J; Huang L
J Biol Chem; 2010 Jul; 285(29):22639-50. PubMed ID: 20460382
[TBL] [Abstract][Full Text] [Related]
11. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA.
Taratula O; Kuzmov A; Shah M; Garbuzenko OB; Minko T
J Control Release; 2013 Nov; 171(3):349-57. PubMed ID: 23648833
[TBL] [Abstract][Full Text] [Related]
12. Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA.
Yu YH; Kim E; Park DE; Shim G; Lee S; Kim YB; Kim CW; Oh YK
Eur J Pharm Biopharm; 2012 Feb; 80(2):268-73. PubMed ID: 22108492
[TBL] [Abstract][Full Text] [Related]
13. Phospholipid-modified PEI-based nanocarriers for in vivo siRNA therapeutics against multidrug-resistant tumors.
Essex S; Navarro G; Sabhachandani P; Chordia A; Trivedi M; Movassaghian S; Torchilin VP
Gene Ther; 2015 Mar; 22(3):257-266. PubMed ID: 25354685
[TBL] [Abstract][Full Text] [Related]
14. Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy.
Chen Y; Wu JJ; Huang L
Mol Ther; 2010 Apr; 18(4):828-34. PubMed ID: 20068551
[TBL] [Abstract][Full Text] [Related]
15. Co-delivery of doxorubicin and siRNA by a simplified platform with oligodeoxynucleotides as a drug carrier.
Liu T; Wang M; Wang T; Yao Y; Zhang N
Colloids Surf B Biointerfaces; 2015 Feb; 126():531-40. PubMed ID: 25618822
[TBL] [Abstract][Full Text] [Related]
16. Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment.
Deng ZJ; Morton SW; Ben-Akiva E; Dreaden EC; Shopsowitz KE; Hammond PT
ACS Nano; 2013 Nov; 7(11):9571-84. PubMed ID: 24144228
[TBL] [Abstract][Full Text] [Related]
17. Codelivery of mTERT siRNA and paclitaxel by chitosan-based nanoparticles promoted synergistic tumor suppression.
Wei W; Lv PP; Chen XM; Yue ZG; Fu Q; Liu SY; Yue H; Ma GH
Biomaterials; 2013 May; 34(15):3912-23. PubMed ID: 23453062
[TBL] [Abstract][Full Text] [Related]
18. Nanotechnology-Based Strategy for Enhancing Therapeutic Efficacy in Pancreatic Cancer: Receptor-Targeted Drug Delivery by Somatostatin Analog.
Gu X; Majumder J; Taratula O; Kuzmov A; Garbuzenko O; Pogrebnyak N; Minko T
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791582
[TBL] [Abstract][Full Text] [Related]
19. Targeted Nanoparticle-Based Diagnostic and Treatment Options for Pancreatic Cancer.
Gu X; Minko T
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672671
[TBL] [Abstract][Full Text] [Related]
20. Nanodelivery systems: An efficient and target-specific approach for drug-resistant cancers.
Ashique S; Garg A; Hussain A; Farid A; Kumar P; Taghizadeh-Hesary F
Cancer Med; 2023 Sep; 12(18):18797-18825. PubMed ID: 37668041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
